



RECEIVED

JAN 07 2002

TECH CENTER 1600/2900

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Eric N. Olson

Jeffrey A. Spencer

Serial No.: 09/908,988

Filed: July 18, 2001

For: METHODS AND COMPOSITIONS FOR  
STABILIZING MICROTUBULES AND  
INTERMEDIATE FILAMENTS IN  
STRIATED MUSCLE CELLS

Group Art Unit: 1632

Examiner: Unknown

Atty. Dkt. No.: MYOG:028US/SLH

RECEIVED

OCT 16 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING  
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

November 9, 2001

Date

Steven L. Nighlander

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10106332/SLH.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: November 9, 2001

Form PTO-1449 (modified)

Atty. Docket No.  
MYOG:028US/SLHSerial No.  
09/908,988

RECEIVED

OCT 16 2002

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
July 18, 2001

Group:

1652/1652 TECH CENTER 1600/2900

U.S. Patent Documents  
See Page 1Foreign Patent Documents  
See Page 1Other Art  
See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
Wum	C1	Antin <i>et al.</i> , "Taxol induces postmitotic myoblasts to assemble interdigitating microtubule-myosin arrays that exclude actin filaments," <i>J. Cell Biol.</i> , 90(2):300-308, 1981.
Wum	C2	Bartkiewicz <i>et al.</i> , "Leucine zipper-mediated homodimerization of the adaptor protein c-Cbl. A role in c-Cbl's tyrosine phosphorylation and its association with epidermal growth factor receptor," <i>J. Biol. Chem.</i> , 274(43):30887-30895, 1999.
Wum	C3	Benjamin <i>et al.</i> , "Temporospatial expression of the small HSP/alpha B-crystallin in cardiac and skeletal muscle during mouse development," <i>Dev. Dyn.</i> , 208(1):75-84, 1997.
Wum	C4	Borden, "RING fingers and B-boxes: zinc-binding protein-protein interaction domains," <i>Biochem. Cell Biol.</i> , 76:351-358, 1998.
Wum	C5	Buchner <i>et al.</i> , "MID2, a homologue of the Opitz syndrome gene MID1: similarities in subcellular localization and differences in expression during development," <i>Hum. Mol. Genet.</i> , 8:1397-1407, 1999.
Wum	C6	Cainarca <i>et al.</i> , "Functional characterization of the Opitz syndrome gene product (midin): evidence for homodimerization and association with microtubules throughout the cell cycle," <i>Hum. Mol. Genet.</i> , 8:1387-1396, 1999.
Wum	C7	Cao <i>et al.</i> , "Involvement of the rfp tripartite motif in protein-protein interactions and subcellular distribution," <i>J. Cell Sci.</i> , 110(Pt 14):1563-1571, 1997.
Wum	C8	De The <i>et al.</i> , "The PML-RAR $\alpha$ fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR," <i>Cell</i> , 66(4):675-684, 1991.

25078623.1

EXAMINER:

DATE CONSIDERED:

22 January 2003

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.  
MYOG:028US/SLHSerial No.  
09/908,988

RECEIVED

List of Patents and Publications for Applicant's

Applicant  
Eric N. Olson  
Jeffrey A. Spencer

OCT 16 2002

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
July 18, 2001Group:  
1632 1652

TECH CENTER 1600/2900

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
WWM	C9	Francis <i>et al.</i> , "Doublecortin is a developmentally regulated, microtubule-associated protein expressed in migrating and differentiating neurons," <i>Neuron.</i> , 23:247-256, 1999.
WWM	C10	Freemont, "Ubiquitination: RING for destruction?" <i>Curr Biol.</i> , 10(2):R84-87, 2000.
WWM	C11	Gleeson <i>et al.</i> , "Doublecortin is a microtubule-associated protein, and is expressed widely by migrating neurons," <i>Neuron.</i> , 2:257-271, 1999.
WWM	C12	Gunderson <i>et al.</i> , "Generation of stable, posttranslationally modified microtubule array is an early event in myogenic differentiation," <i>J. Cell Biol.</i> , 109:2275-2288, 1989.
WWM	C13	Hsieh <i>et al.</i> , "The RING finger/B-Box factor TAM-1 and a retinoblastoma-like protein LIN-35 modulate context-dependent gene silencing in <i>Caenorhabditis elegans</i> ," <i>Genes Dev.</i> , 13(22):2958-2970, 1999.
WWM	C14	Kaech <i>et al.</i> , "Cytoskeletal plasticity in cells expressing neuronal microtubule-associated proteins," <i>Neuron</i> , 17(6):1189-1199, 1996.
WWM	C15	Kaufman <i>et al.</i> , "The M-cadherin catenin complex interacts with microtubules in skeletal muscle cells: implications for the fusion of myoblasts," <i>J. Cell Sci.</i> , 112:55-67, 1999.
WWM	C16	Kosik, "Tau protein and neurodegeneration," <i>Mol. Neurobiol.</i> , 4(3-4):171-179, 1990.
WWM	C17	Li <i>et al.</i> , "The association of <i>Xenopus</i> nuclear factor 7 with subcellular structures is dependent upon phosphorylation and specific domains," <i>Exp. Cell Res.</i> , 13(2):473-481, 1994.
WWM	C18	Lo Nigro <i>et al.</i> , "Point mutations and an intragenic deletion in LIS1, the lissencephaly causative gene in isolated lissencephaly sequence and Miller-Dieker syndrome," <i>Hum. Mol. Genet.</i> , 6(2):157-164, 1997.
WWM	C19	Mangan and Olmsted, "A muscle-specific variant of the microtubule-associated protein 4 (MAP4) is required for myogenesis," <i>Dev.</i> , 122:771-781, 1996.
WWM	C20	Marszalek <i>et al.</i> , "Situs inversus and embryonic ciliary morphogenesis defects in mouse mutants lacking the KIF3A subunit of kinesin-II," <i>Proc. Nat'l Acad. Sci.</i> , 96(9):5043-5048, 1999.
WWM	C21	Nguyen <i>et al.</i> , "Overexpression of full- or partial-length MAP4 stabilizes microtubules and alters cell growth," <i>J. Cell Sci.</i> , 110 ( Pt 2):281-294, 1997.
WWM	C22	Nguyen <i>et al.</i> , "Stabilization and functional modulation of microtubules by microtubule-associated protein 4," <i>Biol. Bull.</i> , 194(3):354-357, 1998.

25078623.1

EXAMINER:

William W. Moore

DATE CONSIDERED:

22 January 2003

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.


Form PTO-1449 (modified)

Atty. Docket No.  
MYOG:028US/SLHSerial No.  
09/908,988

RECEIVED

List of Patents and Publications for Applicant's

OCT 16 2002



INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant  
Eric N. Olson  
Jeffrey A. Spencer  
Filing Date:  
July 18, 2001

Group:

4632/652

TECH CENTER 1600/2900

U.S. Patent Documents  
See Page 1Foreign Patent Documents  
See Page 1Other Art  
See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
WWM	C23	Quaderi <i>et al.</i> , "Opitz G/BBB syndrome, a defect in midline development, is due to mutation in a new RING finger gene on Xp22," <i>Nat. Gen.</i> , 17:285-291, 1997.
WWM	C24	Rawls <i>et al.</i> , "Overlapping functions of the myogenic bHLH genes MRF4 and MyoD revealed in double mutant mice," <i>Development</i> , 125(13):2349-2358, 1998.
WWM	C25	Sapir <i>et al.</i> , "LIS1 is a microtubule-associated phosphoprotein," <i>Eur. J. Biochem.</i> , 265(1):181-188, 1999.
WWM	C26	Sapir <i>et al.</i> , "Reduction of microtubule catastrophe events by LIS1, platelet-activating factor acetylhydrolase subunit," <i>EMBO J.</i> , 16(23):6977-6984, 1997.
WWM	C27	Sato <i>et al.</i> , "Microtubule stabilization in pressure overload cardiac hypertrophy," <i>J. Cell Biol.</i> , 139:963-973, 1997.
WWM	C28	Saurin <i>et al.</i> , "Does this have a familiar RING?" <i>TIBS</i> , 21(6):208-214, 1996.
WWM	C29	Schulze <i>et al.</i> , "Posttranslational modification and microtubule stability," <i>J. Cell Biol.</i> , 105: 2167-2177, 1987.
WWM	C30	Schweiger <i>et al.</i> , "The Opitz syndrome gene product, MID1, associates with microtubules," <i>Proc. Nat'l Acad. Sci. USA</i> , 96:2794-2799, 1999.
WWM	C31	Sotiropoulos <i>et al.</i> , "Signal-regulated activation of serum response factor is mediated by changes in actin dynamics," <i>Cell</i> , 98: 159-169, 1999.
WWM	C32	Spencer and Misra, "Expression of the serum response factor gene is regulated by serum response factor binding sites," <i>J. Biol. Chem.</i> , 271(28):16535-16543, 1996.
WWM	C33	Spencer <i>et al.</i> , "Cooperative transcriptional activation by serum response factor and the high mobility group protein SSRP1," <i>J. Biol. Chem.</i> , 274(22):15686-15693, 1999.
WWM	C34	Stone and Chambers, "Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells," <i>Exp. Cell. Res.</i> , 254: 110-119, 2000.
WWM	C35	Supp <i>et al.</i> , "Targeted deletion of the ATP binding domain of left-right dynein confirms its role in specifying development of left-right asymmetries," <i>Dev.</i> , 126:5495-5504, 1999.
WWM	C36	Takeda <i>et al.</i> , "Left-right asymmetry and kinesin superfamily protein KIF3A: new insights in determination of laterality and mesoderm induction by kif3A <sup>-/-</sup> mice analysis," <i>J. Cell Biol.</i> , 145:825-836, 1999.

25078623.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.  
MYOG:028US/SLHSerial No.  
09/908,988

List of Patents and Publications for Applicant's

Applicant  
Eric N. Olson  
Jeffrey A. SpencerFiling Date:  
July 18, 2001Group:  
1632/1652

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. Patent Documents  
See Page 1Foreign Patent Documents  
See Page 1Other Art  
See Page 1

RECEIVED

JAN 07 2002

TECH CENTER 1600/2900

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
Worm	C37	Takemura <i>et al.</i> , "Increased microtubule stability and alpha tubulin acetylation in cells transfected with microtubule-associated proteins MAP1B, MAP2 or tau," <i>J. Cell Sci.</i> , 103 ( Pt 4):953-964, 1992.
Worm	C38	Tolnay and Probst, "Review: tau protein pathology in Alzheimer's disease and related disorders," <i>Neuropathol. Appl. Neurobiol.</i> , 25(3):171-187, 1999.
Worm	C39	Toyama <i>et al.</i> , "Effects of taxol and Colcemid on myofibrillogenesis," <i>Proc. Natl. Acad. Sci.</i> , 79(21):6556-6560, 1982.
Worm	C40	Wang <i>et al.</i> , "Removal of MAP4 from microtubules in vivo produces no observable phenotype at the cellular level," <i>J. Cell Biol.</i> , 132(3):345-357, 1996.
Worm	C41	Webster, "Neonatal rat cardiomyocytes possess a large population of stable microtubules that is enriched in post-translationally modified subunits," <i>J. Mol. Cell Cardio.</i> , 29:2813-2824, 1997.
Worm	C42	Zetser <i>et al.</i> , "p38 mitogen-activated protein kinase pathway promotes skeletal muscle differentiation. Participation of the MEF2C transcription factor," <i>J. Biol. Chem.</i> , 274: 5193-5200, 1999.

RECEIVED

OCT 16 2002

TECH CENTER 1600/2900

25078623.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)